Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe

Jean Ferrieres, Gaetano Maria De Ferrari, Michel P. Hermans, Moses Elisaf, Peter P. Toth, Martin Horack, Philippe Brudi, Dominik Lautsch, Lori D. Bash, Carl A. Baxter, Veronica Ashton, Baishali Ambegaonkar, Anselm K. Gitt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9% and 41.5% for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.

Original languageEnglish
Pages (from-to)1966-1976
Number of pages11
JournalEuropean Journal of Preventive Cardiology
Volume25
Issue number18
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Dyslipidemias
LDL Cholesterol
Coronary Disease
Acute Coronary Syndrome
Lipids
Therapeutics
Hospitalization
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Survivors
Guidelines
Physicians

Keywords

  • acute coronary syndrome
  • Cholesterol
  • coronary heart disease
  • dyslipidemia
  • statins

ASJC Scopus subject areas

  • Epidemiology
  • Cardiology and Cardiovascular Medicine

Cite this

Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients : Results from DYSIS II Europe. / Ferrieres, Jean; De Ferrari, Gaetano Maria; Hermans, Michel P.; Elisaf, Moses; Toth, Peter P.; Horack, Martin; Brudi, Philippe; Lautsch, Dominik; Bash, Lori D.; Baxter, Carl A.; Ashton, Veronica; Ambegaonkar, Baishali; Gitt, Anselm K.

In: European Journal of Preventive Cardiology, Vol. 25, No. 18, 01.12.2018, p. 1966-1976.

Research output: Contribution to journalArticle

Ferrieres, J, De Ferrari, GM, Hermans, MP, Elisaf, M, Toth, PP, Horack, M, Brudi, P, Lautsch, D, Bash, LD, Baxter, CA, Ashton, V, Ambegaonkar, B & Gitt, AK 2018, 'Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe', European Journal of Preventive Cardiology, vol. 25, no. 18, pp. 1966-1976. https://doi.org/10.1177/2047487318806359
Ferrieres, Jean ; De Ferrari, Gaetano Maria ; Hermans, Michel P. ; Elisaf, Moses ; Toth, Peter P. ; Horack, Martin ; Brudi, Philippe ; Lautsch, Dominik ; Bash, Lori D. ; Baxter, Carl A. ; Ashton, Veronica ; Ambegaonkar, Baishali ; Gitt, Anselm K. / Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients : Results from DYSIS II Europe. In: European Journal of Preventive Cardiology. 2018 ; Vol. 25, No. 18. pp. 1966-1976.
@article{978afd82acf54e9f8348ae7b17e2cd4a,
title = "Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe",
abstract = "BACKGROUND: Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9{\%} and 41.5{\%} for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.",
keywords = "acute coronary syndrome, Cholesterol, coronary heart disease, dyslipidemia, statins",
author = "Jean Ferrieres and {De Ferrari}, {Gaetano Maria} and Hermans, {Michel P.} and Moses Elisaf and Toth, {Peter P.} and Martin Horack and Philippe Brudi and Dominik Lautsch and Bash, {Lori D.} and Baxter, {Carl A.} and Veronica Ashton and Baishali Ambegaonkar and Gitt, {Anselm K.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1177/2047487318806359",
language = "English",
volume = "25",
pages = "1966--1976",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications Ltd",
number = "18",

}

TY - JOUR

T1 - Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients

T2 - Results from DYSIS II Europe

AU - Ferrieres, Jean

AU - De Ferrari, Gaetano Maria

AU - Hermans, Michel P.

AU - Elisaf, Moses

AU - Toth, Peter P.

AU - Horack, Martin

AU - Brudi, Philippe

AU - Lautsch, Dominik

AU - Bash, Lori D.

AU - Baxter, Carl A.

AU - Ashton, Veronica

AU - Ambegaonkar, Baishali

AU - Gitt, Anselm K.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9% and 41.5% for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.

AB - BACKGROUND: Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9% and 41.5% for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.

KW - acute coronary syndrome

KW - Cholesterol

KW - coronary heart disease

KW - dyslipidemia

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85057105509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057105509&partnerID=8YFLogxK

U2 - 10.1177/2047487318806359

DO - 10.1177/2047487318806359

M3 - Article

C2 - 30335504

AN - SCOPUS:85057105509

VL - 25

SP - 1966

EP - 1976

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 18

ER -